Emerging insights into TL1A biology may guide precision therapy for IBD
- Journal
- The Journal of experimental medicine (Q1)
- Published
- 6 August 2026
- Study design
- Narrative review / expert opinion
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Silvia Pires, Wei Yang, Randy S Longman
- PMID
- 42560355
- DOI
- 10.1084/jem.20260874
Why clinicians should know about it
- Picked for Genetics (clinical) (paper of the day, 7 August 2026).
Abstract
Therapeutic blocking antibodies against TNF-like cytokine 1A (TL1A) are emerging as one of the most compelling targets in inflammatory bowel disease (IBD). Preliminary phase 2 studies using TL1A-blocking antibodies have demonstrated some of the highest response rates seen in UC and CD. As the field waits for definitive phase 3 study results, the first of which are expected this summer, mechanistic data continue to expand the biological scope of TL1A in IBD.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.